ReviewCanadian journal of gastroenterology & hepatology2016
Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy.
Review in Canadian journal of gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead.Immunologic research · 2025Review
- B cell depletion for autoimmune liver diseases: A retrospective review of indications and outcomes.JPGN reports · 2024Article
- Precision medicine journey through omics approach.Journal of diabetes and metabolic disorders · 2022Review
- Pharmacokinetic/Pharmacodynamic Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis.The Journal of pharmacology and experimental therapeutics · 2022Article
- [Role of lymphocytes in the pathogenesis of autoimmune hepatitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease.Cells · 2021Article
- Etiopathogenesis and Diagnostic Strategies in Autoimmune Hepatitis.Diagnostics (Basel, Switzerland) · 2021Review
- Tim-3 suppresses autoimmune hepatitis via the p38/MKP-1 pathway in Th17 cells.FEBS open bio · 2021Article
- PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis.Pharmaceutics · 2021Article
- The Role of B Cells in Adult and Paediatric Liver Injury.Frontiers in immunology · 2021Review
- A Case Report of Alloimmune Hepatitis after Direct-acting Antiviral Treatment in a Liver Transplant Patient.Journal of clinical and translational hepatology · 2020Article
- Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients.Frontiers in immunology · 2020Review
- The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.Frontiers in immunology · 2020Review
- Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group.JHEP reports : innovation in hepatology · 2019Article
- Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis.JHEP reports : innovation in hepatology · 2019Article
- Synergistic effects ofAmerican journal of translational research · 2019Article
- The Intracellular Free Zinc Level Is Vital for Treg Function and a Feasible Tool to Discriminate between Treg and Activated Th Cells.International journal of molecular sciences · 2018Article
- The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2018Article
- Salidroside mediates apoptosis and autophagy inhibition in concanavalin A-induced liver injury.Experimental and therapeutic medicine · 2018Article
- Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.Journal of hepatology · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Autoimmune hepatitis (AIH) is an immune mediated liver injury. The precise aetiology of AIH is still unknown but current evidence suggests both genetic and environmental factors are involved. Breakdown in peripheral self-tolerance, and impaired functions of FOXP3(+) regulatory T cell along with effector cell resistance to suppression at the tissue level seem to play an important role in AIH immunopathogenesis. AIH is predominantly a T lymphocytes driven disease but B lymphocytes are also involved in the immunopathology. Innate immune cells are crucial in the initial onset of disease and their response is followed by adaptive T (Th1, Th17, and cytotoxic T cells) and B cell responses evidenced by liver histology and peripheral blood serology. Standard treatment regimens involving steroid and immunosuppressive medications lead to global immune suppression requiring life-long therapy with many side effects. Biologic therapies have been attempted but duration of remission is short-lived. Future direction of diagnosis and treatment for AIH should be guided by "omics" and the immunology profile of the individual patient and clinicians should aim to deliver personalised medicine for their patients. Cell therapy such as infusion of autologous, antigen-specific, and liver-homing regulatory T cells to restore hepatic immune tolerance may soon be a potential future treatment for AIH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.